StreetInsider.com News Articles

Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference

Thu, 15 Oct 2026 16:05:00 -0400

An archived copy of the webcast will be available on the events section of the Company’s website for approximately 90 days following the live presentation.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on

Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference

Thu, 15 Oct 2026 16:05:00 -0400

An archived copy of the webcast will be available on the events section of the Company’s website for approximately 90 days following the live presentation.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on

Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting

Thu, 08 Oct 2026 16:05:00 -0400

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data from Study 250-902 (NCT03227042), a prospective, multicenter, multinational, noninterventional, longitudinal natural history study designed to characterize disease progression in pediatric participants with severe, non-attenuated Sanfilippo Syndrome Type B (MPS IIIB) will be presented at the 55th Child Neurology Society (CNS) Annual Meeting, taking place October 14–17, 2026, in Montréal, Québec, Canada. The poster will be

Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting

Thu, 08 Oct 2026 16:05:00 -0400

B.Riley Reiterates Buy Rating on Spruce Biosciences, Inc. (SPRB)

Mon, 05 Oct 2026 05:07:05 -0400

B.Riley analyst Madison El-Saadi reiterated a Buy rating and $160.00 price target on Spruce Biosciences, Inc. (NASDAQ: SPRB).

The analyst comments "We reiterate our Buy rating and $160 PT on Spruce Biosciences (SPRB) after hosting a recent vNDR with CEO Javier Szwarcberg, M.D., M.P.H., and President and CFO Samir Gharib. Execution and valuation have decoupled heading into the 4Q26 BLA, a gap we view as unsustainable. Since February's FDA alignment on the accelerated approval framework, SPRB has hit every regulatory milestone, completing its first PPQ batch and clearing two pre-BLA meetings. Over the same period, the regulatory tape turned more constructive

Spruce Biosciences (SPRB) Reiterated at Market Outperform by Citizens on TA-ERT Therapy Lead

Thu, 24 Sep 2026 04:19:34 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $144.00 price target on Spruce Biosciences, Inc. (NASDAQ: SPRB).

The analyst commented, "The virtual Advance Sanfilippo Community Conference that wrapped yesterday (9/23) highlighted TA-ERT as the leading emerging therapy for MPS IIIB, with FDA commentary reinforcing the need for regulatory flexibility ahead of SPRB's expected 4Q26 BLA submission. We reiterate our Market Outperform rating and $144 risk-adjusted, DCF-derived price target on Spruce Biosciences."

For an analyst ratings summary and ratings history on Spruce Biosciences, Inc. click here. For more ratings news on Spruce Biosciences, Inc. click here.

Shares of Spruce Biosciences,

Spruce Biosciences (SPRB) Reiterated at Market Outperform by Citizens

Fri, 18 Sep 2026 05:20:06 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $144.00 price target on Spruce Biosciences, Inc. (NASDAQ: SPRB).

The analyst commented, "The FDA granted full approval to Ultragenyx’s (RARE, NC) gene therapy Fayuvi for MPS IIIa ahead of its September 19 PDUFA, which we view as de-risking for TA-ERT’s potential approval for MPS IIIB; we reiterate our Market Outperform rating and $144 risk-adjusted, DCF-derived price target. "

For an analyst ratings summary and ratings history on Spruce Biosciences, Inc. click here. For more ratings news on Spruce Biosciences, Inc. click here.

Shares of Spruce Biosciences, Inc. closed at $53.86 yesterday.

Lake Street Starts Spruce Biosciences, Inc. (SPRB) at Buy

Thu, 17 Sep 2026 07:46:42 -0400

Lake Street analyst Daniel Brims initiates coverage on Spruce Biosciences, Inc. (NASDAQ: SPRB) with a Buy rating and a price target of $149.00.

For an analyst ratings summary and ratings history on Spruce Biosciences, Inc. click here. For more ratings news on Spruce Biosciences, Inc. click here.

Shares of Spruce Biosciences, Inc. closed at $54.16 yesterday.

Spruce Biosciences Announces Launch of MPS3BStudy.com

Wed, 26 Aug 2026 08:00:00 -0400

Website Enables Families and Caregivers of Children with MPS IIIB to Learn About and Register Interest in the TA-ERT Expanded Access Program (EAP) and TrAnsform Confirmatory Study

TA-ERT EAP and TrAnsform Confirmatory Study Both Expected to Initiate in the Fourth Quarter of 2026

Spruce Biosciences Announces Launch of MPS3BStudy.com

Wed, 26 Aug 2026 08:00:00 -0400

Website Enables Families and Caregivers of Children with MPS IIIB to Learn About and Register Interest in the TA-ERT Expanded Access Program (EAP) and TrAnsform Confirmatory Study

TA-ERT EAP and TrAnsform Confirmatory Study Both Expected to Initiate in the Fourth Quarter of 2026

Spruce Biosciences Announces Launch of MPS3BStudy.com

Wed, 26 Aug 2026 08:00:00 -0400

Website Enables Families and Caregivers of Children with MPS IIIB to Learn About and Register Interest in the TA-ERT Expanded Access Program (EAP) and TrAnsform Confirmatory Study

TA-ERT EAP and TrAnsform Confirmatory Study Both Expected to Initiate in the Fourth Quarter of 2026

Spruce Biosciences Announces Launch of MPS3BStudy.com

Wed, 26 Aug 2026 08:00:00 -0400

Website Enables Families and Caregivers of Children with MPS IIIB to Learn About and Register Interest in the TA-ERT Expanded Access Program (EAP) and TrAnsform Confirmatory Study

TA-ERT EAP and TrAnsform Confirmatory Study Both Expected to Initiate in the Fourth Quarter of 2026

H.C. Wainwright Reiterates Buy Rating on Spruce Biosciences, Inc. (SPRB)

Wed, 26 Aug 2026 06:43:02 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $150.00 price target on Spruce Biosciences, Inc. (NASDAQ: SPRB).

The analyst commented: "Recently, Spruce Biosciences announced that it has completed two pre-BLA meetings with the FDA that support the company's plan to submit a Biologics License Application (BLA) for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB) next quarter. The agency found the company's drug substance and drug product analytical comparability strategies reasonable to support the BLA, following technology transfer to a leading global biologics manufacturer. Furthermore, the FDA is aligned with Spruce

Spruce Biosciences BLA filing for rare disease drug on track for 2026

Mon, 24 Aug 2026 08:03:47 -0400

Spruce Biosciences (Nasdaq: SPRB) said it has completed two pre-Biologics License Application (BLA) meetings with the U.S. Food and Drug Administration (FDA) and confirmed its BLA submission for tralesinidase alfa enzyme replacement therapy (TA-ERT) remains on track for the fourth quarter of 2026.

TA-ERT is being developed as a treatment for Sanfilippo Syndrome Type B (MPS IIIB), an ultra-rare fatal genetic disease affecting fewer than one in 200,000 people in the United States. There are currently no FDA-approved therapies for the condition.

According to a company statement, the FDA found Spruce's drug substance and drug product analytical comparability strategies reasonable to support

Spruce Biosciences BLA filing for rare disease drug on track for 2026

Mon, 24 Aug 2026 08:03:47 -0400

According to a company statement, the FDA found Spruce's drug substance and drug product analytical comparability strategies reasonable to support

Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026

Mon, 24 Aug 2026 08:00:00 -0400

FDA Found Spruce's Chemistry, Manufacturing and Controls (CMC) Comparability Strategies Reasonable to Support the BLA Following Technology Transfer to Leading Global Biologics Manufacturer